Analysts Set BioMarin Price Targets at $80–$84 on Amicus Deal
On February 6 Piper Sandler cut its price target on BioMarin to $84 from $122 and maintained an Overweight rating. Earlier, Barclays initiated coverage with an $80 target and Overweight rating, while Canaccord upgraded to Buy, lowering its target to $84, citing the pending Amicus acquisition as a key catalyst.
1. Piper Sandler Revises Price Target
On February 6 Piper Sandler lowered BioMarin’s price target to $84 from $122 while reaffirming its Overweight rating, citing concerns over growth assumptions in the gene therapy pipeline.
2. Barclays Initiates Coverage
Barclays began coverage of BioMarin on January 27 with an Overweight rating and $80 price target, highlighting anticipated sector tailwinds such as mergers, reduced pricing pressure and robust fundamentals in 2026.
3. Canaccord Upgrade Fueled by Acquisition
Canaccord Genuity upgraded BioMarin from Hold to Buy on January 20, trimming its target to $84 and identifying the pending Amicus acquisition as the pivotal catalyst to bridge the company’s valuation gap.